METTL3 and prostate cancer: On the other hand, Jia et al. demonstrated that LXA4 released from prostate cancer cells paradoxically promoted cancer cell survival, likely by inhibiting the RNA modification enzyme methyltransferase-like 3 (METTL3) via the STAT6 signaling pathway.